Clinically relevant brain tumor model and device development for experimental therapeutics

Journal of Analytical Oncology

Volumn 4, Issue 1, 2015, Pages 5-12

  Palanichamy, Kamalakannan ^a   Acus, Kirstin ^a   Jacob, John R ^a   Chakravarti, Arnab ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Brain tumor; Glioblastoma; Glioma stem cell and radiation shield; In vivo model

Indexed keywords

PENTOBARBITAL; TEMOZOLOMIDE;

ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CHEMOSENSITIVITY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SIMULATION; ECHOGRAPHY; ELECTROCARDIOGRAPHY; FLANK MODEL; FLUORESCENCE IMAGING; GENE MUTATION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN TISSUE; INTRACRANIAL MODEL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PARAMETERS; RADIOSENSITIVITY; SUBCUTANEOUS MODEL; THERAPY EFFECT; TRANSGENIC ORGANISM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR DEPTH; TUMOR LENGTH; TUMOR MODEL; TUMOR VOLUME; TUMOR WIDTH;

EID: 84929454343     PISSN: 19277210     EISSN: 19277229     Source Type: Journal    
DOI: 10.6000/1927-7229.2015.04.01.2     Document Type: Article

References (21)

1. Claes A, et al. Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. Brain Pathol 2008; 18(3): 423-33. http://dx.doi.org/10.1111/j.1750-3639.2008.00141.x
2. Lu ZH, et al, establishment of a green fluorescent protein tracing murine model focused on the functions of host components in necrosis repair and the niche of subcutaneously implanted glioma. Oncol Rep 2014; 31(2): 657-64.
3. Shankavaram UT, et al. Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma. J Cell Mol Med 2012; 16(3): 545-54. http://dx.doi.org/10.1111/j.1582-4934.2011.01345.x
4. Oh YT, et al. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma. PLoS One 2014; 9(8): e103327. http://dx.doi.org/10.1371/journal.pone.0103327
5. Kather JN, Kroll J. Transgenic mouse models of corneal neovascularization: new perspectives for angiogenesis research. Invest Ophthalmol Vis Sci 2014; 55(11): 7637-51. http://dx.doi.org/10.1167/iovs.14-15430
6. Ding H, et al. Astrocyte-specific expression of activated p21- ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001; 61(9): 3826-36.
7. Shai R, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003; 22(31): 4918-23. http://dx.doi.org/10.1038/sj.onc.1206753
8. Mischel PS, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003; 22(15): 2361-73. http://dx.doi.org/10.1038/sj.onc.1206344
9. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17(1): 98-110. http://dx.doi.org/10.1016/j.ccr.2009.12.020
10. Hermanson M, et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52(11): 3213-9.
11. Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett 2006; 232(2): 139-47. http://dx.doi.org/10.1016/j.canlet.2005.02.002
12. Libermann TA, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313(5998): 144-7. http://dx.doi.org/10.1038/313144a0
13. Yamaguchi F, et al. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci USA 1994; 91(2): 484-8. http://dx.doi.org/10.1073/pnas.91.2.484
14. Weis J, et al. CNTF and its receptor subunits in human gliomas. J Neurooncol 1999; 44(3): 243-53. http://dx.doi.org/10.1023/A:1006303221064
15. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol 2005; 7(4): 436-51. http://dx.doi.org/10.1215/S1152851705000050
16. Schmidt EE, et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54(24): 6321-4.
17. Ueki K, et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56(1): 150-3.
18. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma:prognostic significance and future therapeutic implications. Adv Anat Pathol 2003; 10(4): 212-7. http://dx.doi.org/10.1097/00125480-200307000-00004
19. Becher OJ, Holland EC. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res 2006; 66(7): 3355-8, discussion 3358-9. http://dx.doi.org/10.1158/0008-5472.CAN-05-3827
20. Fomchenko EI, Holland EC. Mouse models of brain tumors and their applications in preclinical trials. Clin Cancer Res 2006; 12(18): 5288-97. http://dx.doi.org/10.1158/1078-0432.CCR-06-0438
21. Palanichamy K, et al. Novel models to investigate brain tumor stem cell biology. International Journal of Radiation Oncology Biology Physics 2008; 72(1): S53-S54. http://dx.doi.org/10.1016/j.ijrobp.2008.06.887